All Oncology News

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators.

Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.

Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.

Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.

The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.

Megan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.

R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies such as pimicotinib in TGCT enables a tumor biology–informed approach to care.

Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.

An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC

The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.

Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.

Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.

Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

Treatment with gedatolisib-based regimens led to significant PFS benefits vs alpelisib/fulvestrant in PIK3CA-mutant HR-positive advanced breast cancer.

Research from Roswell Park Comprehensive Cancer outlines other potential uses for CDK inhibition in breast cancer management.

Pelareorep plus bevacizumab and FOLFIRI showed a 33% response rate and 19.5-month median response duration in RAS-mutant MSS CRC.

The FDA approved Guardant360 CDx as a companion diagnostic for vepdegestrant in ER-positive advanced or metastatic breast cancer with ESR1 mutations.

Duvelisib demonstrated deep, durable responses and promising efficacy data across peripheral T-cell lymphoma subgroups.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

A one-stop-shop for regulatory updates across GI malignancies from the past month.